+

PL2550363T3 - Myszy adam6 - Google Patents

Myszy adam6

Info

Publication number
PL2550363T3
PL2550363T3 PL12716101T PL12716101T PL2550363T3 PL 2550363 T3 PL2550363 T3 PL 2550363T3 PL 12716101 T PL12716101 T PL 12716101T PL 12716101 T PL12716101 T PL 12716101T PL 2550363 T3 PL2550363 T3 PL 2550363T3
Authority
PL
Poland
Prior art keywords
adam6 mice
adam6
mice
Prior art date
Application number
PL12716101T
Other languages
English (en)
Inventor
Lynn Macdonald
Sean Stevens
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45998616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2550363(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PL2550363T3 publication Critical patent/PL2550363T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/22—Heating, cooling or ventilating [HVAC] devices the heat being derived otherwise than from the propulsion plant
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/3228—Cooling devices using compression characterised by refrigerant circuit configurations
    • B60H1/32281—Cooling devices using compression characterised by refrigerant circuit configurations comprising a single secondary circuit, e.g. at evaporator or condenser side
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/323—Cooling devices using compression characterised by comprising auxiliary or multiple systems, e.g. plurality of evaporators, or by involving auxiliary cooling devices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00642—Control systems or circuits; Control members or indication devices for heating, cooling or ventilating devices
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/00192—Distribution of conditionned air to left and right part of passenger compartment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/002—Distribution of conditionned air to front and rear part of passenger compartment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Thermal Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
PL12716101T 2011-02-25 2012-02-24 Myszy adam6 PL2550363T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161446895P 2011-02-25 2011-02-25
US201161497650P 2011-06-16 2011-06-16
US201261595200P 2012-02-06 2012-02-06
PCT/US2012/026416 WO2012141798A1 (en) 2011-02-25 2012-02-24 Adam6 mice
EP12716101.6A EP2550363B1 (en) 2011-02-25 2012-02-24 Adam6 mice

Publications (1)

Publication Number Publication Date
PL2550363T3 true PL2550363T3 (pl) 2015-05-29

Family

ID=45998616

Family Applications (5)

Application Number Title Priority Date Filing Date
PL12716101T PL2550363T3 (pl) 2011-02-25 2012-02-24 Myszy adam6
PL14154967T PL2738259T3 (pl) 2011-02-25 2012-02-24 Myszy adam6
PL14154918.8T PL2738258T5 (pl) 2011-02-25 2012-02-24 Myszy adam6
PL22156414.9T PL4067496T3 (pl) 2011-02-25 2012-02-24 Myszy adam6
PL12192727.1T PL2578688T5 (pl) 2011-02-25 2012-02-24 Myszy adam6

Family Applications After (4)

Application Number Title Priority Date Filing Date
PL14154967T PL2738259T3 (pl) 2011-02-25 2012-02-24 Myszy adam6
PL14154918.8T PL2738258T5 (pl) 2011-02-25 2012-02-24 Myszy adam6
PL22156414.9T PL4067496T3 (pl) 2011-02-25 2012-02-24 Myszy adam6
PL12192727.1T PL2578688T5 (pl) 2011-02-25 2012-02-24 Myszy adam6

Country Status (32)

Country Link
US (12) US8642835B2 (pl)
EP (7) EP2738258B2 (pl)
JP (8) JP2014507137A (pl)
KR (1) KR101387377B1 (pl)
CN (2) CN103429746B (pl)
AU (5) AU2012243291B2 (pl)
BR (1) BR112013021771B1 (pl)
CA (1) CA2820824A1 (pl)
CY (5) CY1116301T1 (pl)
DE (5) DE12716101T1 (pl)
DK (6) DK2738258T4 (pl)
ES (6) ES2805364T3 (pl)
FI (3) FI2578688T4 (pl)
HK (2) HK1201292A1 (pl)
HR (5) HRP20230526T1 (pl)
HU (5) HUE062552T2 (pl)
IL (4) IL226727A (pl)
IN (1) IN2013CN07629A (pl)
LT (4) LT2738259T (pl)
ME (3) ME02106B (pl)
MX (3) MX343009B (pl)
MY (1) MY172713A (pl)
NZ (2) NZ731926A (pl)
PL (5) PL2550363T3 (pl)
PT (5) PT2550363E (pl)
RS (5) RS59661B2 (pl)
RU (2) RU2582261C2 (pl)
SG (4) SG10201913160QA (pl)
SI (5) SI2738259T1 (pl)
SM (5) SMT201900744T1 (pl)
WO (1) WO2012141798A1 (pl)
ZA (1) ZA201305998B (pl)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN100480260C (zh) 2002-07-18 2009-04-22 克鲁塞尔荷兰公司 抗体混合物的重组生产
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
EP2395016A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP3272770B1 (en) 2004-07-22 2023-12-20 Erasmus University Medical Center Rotterdam Method for the production of a vh heavy chain-only antibody in a transgenic mammal and binding polypeptide complex consisting of a dimer of a first chain and a second chain wherein each chain consists of two antigen-specific vh binding domains linked by a dimerisation domain
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
CN105340834B (zh) 2009-07-08 2018-11-06 科马布有限公司 动物模型及治疗分子
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
PT2501817E (pt) 2010-02-08 2015-11-04 Regeneron Pharma Rato de cadeia leve comum
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
PL2601298T3 (pl) 2010-08-02 2017-03-31 Regeneron Pharmaceuticals, Inc. Myszy wytwarzające białka wiążące obejmujące domeny vl
DK2738258T4 (da) 2011-02-25 2023-05-08 Regeneron Pharma ADAM6-mus
AU2012279018B2 (en) 2011-07-05 2017-06-08 Children's Medical Center Corporation N-terminal deleted GP120 immunogens
DK3572517T3 (da) 2011-08-05 2021-06-14 Regeneron Pharma Humaniserede, universelle letkæde-mus
EP3741862A1 (en) 2011-09-19 2020-11-25 Kymab Limited Animals, repertoires & methods for the production of human antibodies
JP2014533930A (ja) 2011-09-19 2014-12-18 カイマブ・リミテッド 免疫グロブリン遺伝子多様性の操作およびマルチ抗体治療薬
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
CA2850745C (en) 2011-10-03 2022-12-13 Duke University Vaccine
RU2743589C2 (ru) * 2011-10-17 2021-02-20 Регенерон Фармасьютикалс, Инк. Мыши с ограниченной тяжелой цепью иммуноглобулина
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
DK2793567T3 (en) 2011-12-20 2019-04-15 Regeneron Pharma Humanized light chain mice
SG10201606256TA (en) * 2012-02-01 2016-09-29 Regeneron Pharma Humanized rodents that express heavy chains containing vl domains
SG11201405164QA (en) 2012-03-16 2014-10-30 Regeneron Pharma Mice that produce antigen-binding proteins with ph-dependent binding characteristics
SI2825036T1 (en) 2012-03-16 2018-08-31 Regeneron Pharmaceuticals, Inc. Light chain antibodies with built-in histidine and genetically modified rodents for their formation
NZ712508A (en) 2012-03-16 2018-06-29 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
CN107383197B (zh) 2012-04-20 2021-12-10 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
KR20240042174A (ko) * 2012-06-12 2024-04-01 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물
WO2014124156A1 (en) 2013-02-06 2014-08-14 Regeneron Pharmaceuticals, Inc. B cell lineage based immunogen design with humanized animals
KR101764800B1 (ko) 2013-02-20 2017-08-04 리제너론 파마슈티칼스 인코포레이티드 변형된 면역글로불린 중쇄 서열을 갖는 비인간 동물
ES2829376T3 (es) * 2013-03-14 2021-05-31 Univ Erasmus Med Ct Rotterdam Mamífero no humano transgénico para la producción de anticuerpos
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
TW201546284A (zh) 2013-10-01 2015-12-16 Kymab Ltd 動物模式及治療分子
JP6267986B2 (ja) * 2014-02-13 2018-01-24 株式会社特殊免疫研究所 ヒトの特定分子と結合する分子標的物質のｉｎｖｉｖｏ評価法
AU2015231025A1 (en) 2014-03-21 2016-09-15 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
SG10201808225TA (en) 2014-03-21 2018-10-30 Regeneron Pharma Non-human animals that make single domain binding proteins
US20160081314A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric Antigen Receptors
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
KR20230006929A (ko) 2016-01-13 2023-01-11 리제너론 파마슈티칼스 인코포레이티드 조작된 중쇄 다양성 영역을 갖는 설치류
CA3014208A1 (en) 2016-02-16 2017-08-24 Regeneron Pharamaceuticals, Inc. Non-human animals having a mutant kynureninase gene
KR102628909B1 (ko) * 2016-05-20 2024-01-25 리제너론 파마슈티칼스 인코포레이티드 다중 가이드 RNAs를 이용한 면역학적 내성 파괴 방법
RU2753585C2 (ru) 2016-06-03 2021-08-18 Регенерон Фармасьютикалз, Инк. Животные, не являющиеся человеком, экспрессирующие экзогенную терминальную дезоксинуклеотидилтрансферазу
WO2017214089A1 (en) * 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
KR20240055863A (ko) 2016-11-04 2024-04-29 리제너론 파마슈티칼스 인코포레이티드 조작된 면역글로불린 람다 경쇄 유전자좌를 갖는 비인간 동물
US11122042B1 (en) 2017-05-12 2021-09-14 F5 Networks, Inc. Methods for dynamically managing user access control and devices thereof
KR102760654B1 (ko) 2017-06-07 2025-02-04 리제너론 파마슈티칼스 인코포레이티드 효소 내재화를 위한 조성물 및 방법
IL274797B1 (en) 2017-12-05 2025-02-01 Regeneron Pharma Non-human animals with engineered lambda immunoglobulin light chains and uses thereof
CA3090519A1 (en) 2018-02-07 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
KR20200133339A (ko) 2018-03-21 2020-11-27 크리스탈 바이오사이언스 주식회사 인간 항체를 생산하는 트랜스제닉 닭
SMT202500038T1 (it) 2018-03-24 2025-03-12 Regeneron Pharma Topi o ratti geneticamente modificati per la generazione di anticorpi terapeutici contro complessi peptide-mhc, metodi di produzione e loro utilizzo
TW202431987A (zh) 2018-03-26 2024-08-16 美商再生元醫藥公司 用於測試治療藥劑之人類化囓齒動物
AU2019269685A1 (en) 2018-05-17 2020-12-03 Regeneron Pharmaceuticals, Inc. Anti-CD63 antibodies, conjugates, and uses thereof
WO2019240999A1 (en) * 2018-06-13 2019-12-19 Crystal Bioscience Inc. Camelization of a human variable domain by gene conversion
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
AU2020226445A1 (en) 2019-02-18 2021-07-08 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
EP3927153A1 (en) 2019-02-22 2021-12-29 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
TW202110323A (zh) 2019-06-05 2021-03-16 美商再生元醫藥公司 具有表現自κ 基因座的有限λ 輕鏈組庫的非人類動物及其用途
DK3785536T3 (da) * 2019-08-28 2022-03-28 Trianni Inc Adam6-knockin-mus
WO2021113297A1 (en) 2019-12-02 2021-06-10 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
AU2021283564A1 (en) 2020-06-02 2022-12-08 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with common light chain immunoglobulin locus
TW202229328A (zh) 2020-09-11 2022-08-01 美商再生元醫藥公司 抗原特異性抗體之鑑定及產生
IL303626A (en) 2020-12-16 2023-08-01 Regeneron Pharma Mice expressing humanized fc alpha receptors
CN116635413A (zh) 2020-12-23 2023-08-22 再生元制药公司 用于获得结合跨膜蛋白的抗体的方法和生产所述抗体的细胞
KR20230125236A (ko) 2020-12-23 2023-08-29 리제너론 파마슈티칼스 인코포레이티드 앵커 변형된 항체를 암호화하는 핵산 및 이의 사용
JP7579462B2 (ja) 2021-04-20 2024-11-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アルテミンに対するヒト抗体及びその使用方法
EP4554977A1 (en) 2022-07-12 2025-05-21 Regeneron Pharmaceuticals, Inc. Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof
WO2024173248A1 (en) 2023-02-13 2024-08-22 Regeneron Pharmaceuticals, Inc. Treatment of muscle related disorders with anti-human cacng1 antibodies
WO2024229105A1 (en) 2023-05-02 2024-11-07 Regeneron Pharmaceuticals, Inc. Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells
WO2025014533A1 (en) 2023-07-10 2025-01-16 Regeneron Pharmaceuticals, Inc. Anti-human cacng1 antibody-drug conjugates and uses thereof
WO2025055311A1 (zh) 2023-09-15 2025-03-20 赛业（苏州）生物科技有限公司 用于制备抗体的基因修饰小鼠及其制备方法
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CZ140195A3 (en) * 1992-12-01 1996-06-12 Protein Desing Labs Humanized antibodies reacting with l-selectin
EP0942968B1 (en) * 1996-12-03 2008-02-27 Amgen Fremont Inc. Fully human antibodies that bind EGFR
CN1203922A (zh) * 1997-03-21 1999-01-06 三共株式会社 人源化抗人fas抗体
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
RU10506U1 (ru) 1999-04-08 1999-08-16 Кривулин Виталий Николаевич Ручной культиватор
JP2003501016A (ja) * 1999-05-27 2003-01-14 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Ａｄａｍのポリヌクレオチドおよびポリペプチド
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7034134B2 (en) 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
ATE398172T1 (de) * 2001-05-11 2008-07-15 Kirin Pharma Kk Künstliches menschliches chromosom mit dem gen für die lambda-leichte kette menschlicher antikörper
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
US20030108925A1 (en) 2001-10-05 2003-06-12 U.S. Epa Genetic testing for male factor infertility
JP4099646B2 (ja) 2002-06-04 2008-06-11 株式会社安川電機 ボイスコイルモータ
CN100480260C (zh) 2002-07-18 2009-04-22 克鲁塞尔荷兰公司 抗体混合物的重组生产
RU2251699C1 (ru) 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
DK1802193T3 (da) 2004-10-19 2014-06-10 Regeneron Pharma Fremgangsmåde til frembringelse af en homozygot mus til genetisk modifikation
DE602005011421D1 (de) 2005-06-30 2009-01-15 Borealis Tech Oy Überzug-Schicht für Energie- oder Kommunikationskabel
JP5514539B2 (ja) * 2006-03-31 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
EP2185692A4 (en) 2007-08-10 2012-05-02 Medarex Inc HCO32 AND HCO27 AND RELATED EXAMPLES
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
KR102362774B1 (ko) 2008-09-30 2022-02-15 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 인간 이외의 포유동물
CN112680475B (zh) * 2008-12-18 2024-11-12 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
JP5399140B2 (ja) * 2009-06-18 2014-01-29 株式会社タイトー モールス信号通信システム
CN105340834B (zh) 2009-07-08 2018-11-06 科马布有限公司 动物模型及治疗分子
PL2954779T3 (pl) 2009-12-10 2019-07-31 Regeneron Pharmaceuticals, Inc. Myszy wytwarzające przeciwciała ciężkołańcuchowe
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
PT2501817E (pt) 2010-02-08 2015-11-04 Regeneron Pharma Rato de cadeia leve comum
NZ605966A (en) 2010-06-17 2015-04-24 Kymab Ltd Animal models and therapeutic molecules
DK2738258T4 (da) 2011-02-25 2023-05-08 Regeneron Pharma ADAM6-mus
DK3572517T3 (da) 2011-08-05 2021-06-14 Regeneron Pharma Humaniserede, universelle letkæde-mus
RU2743589C2 (ru) 2011-10-17 2021-02-20 Регенерон Фармасьютикалс, Инк. Мыши с ограниченной тяжелой цепью иммуноглобулина
GB201118579D0 (en) 2011-10-27 2011-12-07 Micromass Ltd Control of ion populations
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
DK2793567T3 (en) 2011-12-20 2019-04-15 Regeneron Pharma Humanized light chain mice
KR20240042174A (ko) 2012-06-12 2024-04-01 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물

Also Published As

Publication number Publication date
US20150210776A1 (en) 2015-07-30
DK2813573T1 (da) 2015-01-12
RU2016109443A (ru) 2018-11-26
CN105861548A (zh) 2016-08-17
US10905109B2 (en) 2021-02-02
DE14154918T1 (de) 2014-08-21
US20140213773A1 (en) 2014-07-31
HRP20200294T1 (hr) 2020-05-29
RU2013125717A (ru) 2014-12-10
JP2016135143A (ja) 2016-07-28
PT2738258T (pt) 2019-12-10
SI2578688T1 (sl) 2019-11-29
DK2738259T1 (da) 2014-11-24
US12207628B2 (en) 2025-01-28
LT2738258T (lt) 2020-01-10
JP2018143250A (ja) 2018-09-20
CN103429746A (zh) 2013-12-04
DK2738258T1 (da) 2014-11-24
US20180346599A1 (en) 2018-12-06
US20180345760A1 (en) 2018-12-06
HUE047687T2 (hu) 2020-05-28
PL4067496T3 (pl) 2023-07-31
KR101387377B1 (ko) 2014-04-21
CY1122820T1 (el) 2021-05-05
HK1174490A1 (en) 2013-06-14
NZ718688A (en) 2017-07-28
HRP20192311T1 (hr) 2020-03-20
US9932408B2 (en) 2018-04-03
EP2578688B2 (en) 2023-02-08
DK2738258T4 (da) 2023-05-08
US20130254911A1 (en) 2013-09-26
DK2738258T3 (da) 2019-12-16
DK2738259T3 (da) 2020-02-17
IN2013CN07629A (pl) 2015-08-07
HRP20191895T1 (hr) 2020-01-10
LT2578688T (lt) 2019-11-11
IL226727A (en) 2016-08-31
RS59413B1 (sr) 2019-11-29
SG10201913160QA (en) 2020-03-30
PL2738259T3 (pl) 2020-08-24
SI2738259T1 (sl) 2020-06-30
DK4067496T3 (da) 2023-06-26
US20180346598A1 (en) 2018-12-06
LT4067496T (lt) 2023-06-12
EP2550363B1 (en) 2014-12-10
MX343009B (es) 2016-10-21
US20240306617A1 (en) 2024-09-19
PL2578688T5 (pl) 2023-05-29
SMT201900744T1 (it) 2020-01-14
EP2578688B1 (en) 2019-07-24
ME03537B (pl) 2020-04-20
PT2578688T (pt) 2019-10-24
HRP20230526T1 (hr) 2023-09-01
DE12192727T1 (de) 2013-07-11
NZ776770A (en) 2023-03-31
SI2578688T2 (sl) 2023-05-31
JP2014507137A (ja) 2014-03-27
RS64280B1 (sr) 2023-07-31
HUE046081T2 (hu) 2020-01-28
JP2014110814A (ja) 2014-06-19
SMT202300173T1 (it) 2023-07-20
RU2582261C2 (ru) 2016-04-20
CN105861548B (zh) 2020-01-10
US9944716B2 (en) 2018-04-17
NZ612643A (en) 2015-06-26
PL2578688T3 (pl) 2020-05-18
PT4067496T (pt) 2023-06-07
DE14176593T1 (de) 2015-03-05
RS59413B2 (sr) 2023-06-30
BR112013021771A2 (pt) 2017-07-04
RS59661B2 (sr) 2023-06-30
EP2813573B1 (en) 2020-04-22
AU2015238806A1 (en) 2015-10-29
IL268671B (en) 2020-05-31
US10072095B2 (en) 2018-09-11
NZ703609A (en) 2016-04-29
SG10201913155QA (en) 2020-02-27
BR112013021771B1 (pt) 2022-11-16
US20210105984A1 (en) 2021-04-15
SI2738258T2 (sl) 2023-05-31
CY1122205T1 (el) 2020-11-25
IL261243A (en) 2018-10-31
RS59661B1 (sr) 2020-01-31
EP2738259A2 (en) 2014-06-04
HRP20192311T4 (hr) 2023-05-12
DK2578688T3 (da) 2019-10-28
AU2020201279A1 (en) 2020-03-12
ZA201305998B (en) 2016-07-27
MX2013009649A (es) 2013-09-26
US10577430B2 (en) 2020-03-03
AU2012243291B2 (en) 2015-07-09
US8642835B2 (en) 2014-02-04
AU2017251802A1 (en) 2017-11-16
EP2738258B2 (en) 2023-02-01
NZ797720A (en) 2024-09-27
SMT201900581T1 (it) 2019-11-13
MX2020009714A (es) 2020-10-07
ES2946169T3 (es) 2023-07-13
US20150201589A1 (en) 2015-07-23
SG192933A1 (en) 2013-09-30
JP2025032218A (ja) 2025-03-11
CY1122459T1 (el) 2021-01-27
ES2748832T5 (es) 2023-06-08
FI4067496T3 (fi) 2023-05-24
HK1201292A1 (en) 2015-08-28
HRP20191895T4 (hr) 2023-05-12
PT2550363E (pt) 2015-03-16
MY172713A (en) 2019-12-11
HUE024534T2 (hu) 2016-01-28
DK2550363T3 (en) 2015-03-23
US10905108B2 (en) 2021-02-02
FI2578688T4 (fi) 2023-05-05
RU2722373C2 (ru) 2020-05-29
JP2022071051A (ja) 2022-05-13
EP4067496B1 (en) 2023-03-29
RS53880B1 (en) 2015-08-31
US10694725B2 (en) 2020-06-30
DK2578688T1 (da) 2014-11-24
CY1126091T1 (el) 2023-11-15
DE12716101T1 (de) 2013-05-08
ME02106B (me) 2015-10-20
DE14154967T1 (de) 2014-08-28
CA2820824A1 (en) 2012-10-18
DK4067496T5 (da) 2024-07-22
IL273986B (en) 2021-04-29
JP2015107131A (ja) 2015-06-11
RU2016109443A3 (pl) 2019-07-24
LT2738259T (lt) 2020-03-10
ES2805364T3 (es) 2021-02-11
WO2012141798A1 (en) 2012-10-18
IL273986A (en) 2020-05-31
ES2532487T3 (es) 2015-03-27
CY1116301T1 (el) 2017-02-08
HUE046746T2 (hu) 2020-03-30
EP2738258A3 (en) 2014-09-24
PT2738259T (pt) 2020-02-18
AU2012243291A1 (en) 2013-05-09
AU2022206806A1 (en) 2022-08-18
ES2770424T3 (es) 2020-07-01
SG10201405135RA (en) 2014-10-30
MX375115B (es) 2025-03-06
US20210105985A1 (en) 2021-04-15
EP2813573A1 (en) 2014-12-17
JP2019187446A (ja) 2019-10-31
US20120322108A1 (en) 2012-12-20
FI2738258T4 (fi) 2023-05-05
IL261243B (en) 2019-08-29
PL2738258T3 (pl) 2020-08-24
HRP20150262T1 (hr) 2015-04-10
CN103429746B (zh) 2016-05-11
EP2578688A1 (en) 2013-04-10
ES2758974T5 (es) 2023-06-08
US11950578B2 (en) 2024-04-09
SMT201500061B (it) 2015-05-05
ES2748832T3 (es) 2020-03-18
EP3744850A1 (en) 2020-12-02
PL2738258T5 (pl) 2023-05-15
SI2550363T1 (sl) 2015-04-30
NZ731926A (en) 2021-07-30
DK2578688T4 (da) 2023-05-08
RS59929B1 (sr) 2020-03-31
US8697940B2 (en) 2014-04-15
EP2738259A3 (en) 2014-07-30
ES2758974T3 (es) 2020-05-07
US20180362663A1 (en) 2018-12-20
IL268671A (en) 2019-10-31
ME03732B (me) 2021-01-20
SI2738258T1 (sl) 2020-01-31
JP5866127B2 (ja) 2016-02-17
SMT202000112T1 (it) 2020-05-08
EP2738258A2 (en) 2014-06-04
SI4067496T1 (sl) 2023-07-31
EP2550363A1 (en) 2013-01-30
EP2738259B1 (en) 2019-11-27
HUE062552T2 (hu) 2023-11-28
KR20130116375A (ko) 2013-10-23
EP2738258B1 (en) 2019-09-25
EP4067496A1 (en) 2022-10-05

Similar Documents

Publication Publication Date Title
IL273986B (en) adam6 mice
AP2014007621A0 (en) 2-Thiopyrimidinones
AU339404S (en) Pen
GB201109865D0 (en) Touchiness interaction
AP00723S1 (en) Autorickshaw
AU2011303V (en) Silverado Dianella tasmanica
AP2011000390S (en) Kuppkraft
GB201107161D0 (en) Corcost-ZZ600
AU2011035V (en) DBK02 Babingtonia virgata
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载